Diseases & Conditions
Grants & Contracts
News & Events
May 19, 2022
The national EV-D68 pilot study is part of PREMISE, the Pandemic Response Repository through Microbial and Immune Surveillance and Epidemiology. PREMISE is an initiative from NIAID’S Vaccine Research Center (VRC) that began in early 2021.
May 11, 2022
NIAID researchers designed a ferritin nanoparticle flu vaccine and tested it in people with and without immunological experience of the flu virus that caused the 1957 pandemic. The experimental vaccine prompted immune responses that suggested this kind of vaccine could provide long-lasting protection against many flu subtypes.
May 18, 2021
While implementation of highly effective HIV treatment and prevention tools has reduced the HIV pandemic worldwide, development of a safe and even modestly effective vaccine would hasten progress toward a durable end of the HIV pandemic. Today, on HIV Vaccine Awareness Day, NIAID acknowledges both the progress that has been made in HIV vaccine development and the challenges that remain. We also reflect on how advances in HIV vaccinology paved the way for COVID-19 vaccine development.
May 06, 2021
Scientists at NIAID’s Vaccine Research Center and their NIAID-supported colleagues at the University of Washington School of Medicine used tiny nanoparticles to make a huge leap towards the goal of a universal flu vaccine.
July 20, 2020
NIAID and IAVI, a nonprofit scientific research organization, are collaborating to develop antibody-based products for HIV prevention and treatment.
April 17, 2020
A NIAID-led trial has proven an experimental chikungunya vaccine to be both safe and to confer durable immune responses in healthy volunteers.
February 19, 2020
NIAID scientists and investigators from UT Austin identified the atomic structure of an important protein on the surface of the novel coronavirus.